Table 1.
Characteristics (n=148)
| Group denomination, number of patients |
Group 1 (n=98) | Group 2 (n=19) | Group 3 (n=31) |
|---|---|---|---|
| Years of transplantation | 1971–1984 | 1981–1988* | 1989–2010 |
| Age, years | |||
| Median (range) | 13.1 (1.9–19) | 12.5 (1.8–18.8) | 10.9 (2.0–18.3) |
| Gender, n (%) | |||
| Male | 56 (57%) | 8 (42%) | 20 (65%) |
| Female | 42 (43%) | 11 (58%) | 11 (35%) |
| Aetiology of aplastic anaemia, (n) | |||
| Unknown | 81 | 19 | 26 |
| Hepatitis | 7 | 0 | 5 |
| Drugs/chemicals | 8 | 0 | 0 |
| Paroxysmal nocturnal haemoglobinuria | 2 | 0 | 0 |
| Number of patients who received transfusions before marrow transplantation, n (%) | |||
| Red blood cell | 75 (77%) | 15 (79%) | 28 (90%) |
| Platelet | 71 (72%) | 14 (74%) | 28 (90%) |
| Number of patients who received treatment before marrow transplantation, n (%) | |||
| Androgens | 35 (36%) | 3 (16%) | 0 (0%) |
| Steroids | 55 (56%) | 7 (37%) | 6 (19%) |
| ATG or other agent | 0 (0%) | 1 (5%) | 3 (10%) |
| Months from diagnosis to marrow transplantation | |||
| Median, (range) | 1 (0–108) | 1.4 (0.3–5.8) | 1.2 (0.4–24.0) |
| Preparative regimen | CY | CY | CY/ATG |
| GVHD prophylaxis | MTX (n=95) CSP (n=3) |
MTX/CSP (n=19) | MTX/CSP (n=31) |
| Nucleated marrow cell dose (× 108/kg) | |||
| Median, (range) | 3.7 (0.6–15.5) | 2.7 (0.7–9.6) | 2.8 (0.9–6.2) |
| Follow-up living patients, years | |||
| Median, (range) | 31.1 (11–37.2) | 23 (15.2–27.1) | 6.1 (0.3–21.5) |
ATG=anti-thymocyte globulin; CSP=ciclosporin; CY = cyclophosphamide, GVHD=graft versus host disease; kg=kilogram; MTX=methotrexate; n=number
*
There was one patient included in group 2 who received a transplant in 1995 following conditioning with CY and CSP/MTX for GVHD prevention. This patient had a positive skin test to ATG and was therefore unable to receive ATG.